 <h1>Ixempra Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ixabepilone</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ixabepilone. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ixempra.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ixabepilone: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT greater than 2.5 times the ULN or bilirubin greater than 1 time the ULN due to an increased risk of toxicity and neutropenia-related death.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ixabepilone (the active ingredient contained in Ixempra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ixabepilone:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>body aches or pain</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>burning pain on urination</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>difficult or labored breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>nasal congestion</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>red, swelling, or painful skin</li>
<li>runny nose</li>
<li>scaling of the skin on the hands and feet</li>
<li>shortness of breath</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips, tongue, or inside the mouth</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>tingling of the hands and feet</li>
<li>troubled breathing with exertion</li>
<li>ulceration of the skin</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain</li>
<li>weakness in the arms, hands, legs, or feet</li>
<li>wheezing</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding gums</li>
<li>blood in the urine or stools</li>
<li>confusion</li>
<li>decreased urination</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>hives</li>
<li>hoarseness</li>
<li>increase in heart rate</li>
<li>irritation</li>
<li>itching</li>
<li>joint pain, stiffness, or swelling</li>
<li>lightheadedness</li>
<li>pinpoint red spots on the skin</li>
<li>rapid breathing</li>
<li>rash</li>
<li>sunken eyes</li>
<li>swelling of the eyelids, face, or lips</li>
<li>thirst</li>
<li>trouble with swallowing</li>
<li>wrinkled skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ixabepilone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bad, unusual, or unpleasant (after) taste</li>
<li>bone pain</li>
<li>change in taste</li>
<li>cracked lips</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
<li>discoloration of the fingernails or toenails</li>
<li>feeling of warmth</li>
<li>hair loss or thinning of the hair</li>
<li>heartburn</li>
<li>lack or loss of strength</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>stomach pain</li>
<li>sudden sweating</li>
<li>swelling or inflammation of the mouth</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Darkening of the skin</li>
<li>flaking and falling off of the skin</li>
<li>sleeplessness</li>
<li>trouble with sleeping</li>
<li>unable to sleep</li>
<li>watering of the eyes</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ixabepilone: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (Grade 4) (36%), leukopenia (41%)</p>
<p><b>Common</b> (1% to 10%): Febrile neutropenia, infection with neutropenia, anemia, thrombocytopenia</p>
<p><b>Frequency not reported</b>: Coagulopathy, lymphopenia, hemorrhage<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Flushing, rash, dyspnea, bronchospasm, anaphylaxis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (all Grades) (67%), sensory neuropathy (65%), peripheral neuropathy (Grade 3 or 4) (23%), motor neuropathy (16%), taste disorder (12%)</p>
<p><b>Common</b> (1% to 10%): Headache, dizziness</p>
<p><b>Frequency not reported</b>: Cognitive disorder, syncope, cerebral hemorrhage, abnormal coordination, lethargy<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Myocardial ischemia, ventricular dysfunction, hot flush </p>
<p><b>Uncommon</b> (0.1% to 1%): Supraventricular arrhythmia</p>
<p><b>Frequency not reported</b>: Myocardial infarction, supraventricular arrhythmia, left ventricular dysfunction, angina pectoris, atrial flutter, cardiomyopathy, myocardial ischemia, hypotension, thrombosis, embolism, hypovolemic shock, vasculitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia/arthralgia (39%), musculoskeletal pain (23%)</p>
<p><b>Frequency not reported</b>: Muscular weakness, muscle spasms, trismus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (53%), abdominal pain (24%), constipation (22%), stomatitis/mucositis, diarrhea</p>
<p><b>Common</b> (1% to 10%): Dehydration, gastroesophageal reflux disease</p>
<p><b>Frequency not reported</b>: Enterocolitis, ileus, colitis, impaired gastric emptying, esophagitis, dysphagia, gastritis, GI hemorrhage<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia syndrome (64%), alopecia (31%), nail disorder (24%), skin rash (17%), skin hyperpigmentation (14%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, skin exfoliation</p>
<p><b>Frequency not reported</b>: Erythema multiforme</p>
<p><b>Postmarketing reports</b>: Radiation recall<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, dyspnea, cough</p>
<p><b>Frequency not reported</b>: Pneumonia, laryngitis, lower respiratory tract infection, pneumonitis, hypoxia, respiratory failure, acute pulmonary edema, dysphonia, pharyngolaryngeal pain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Acute hepatic failure, jaundice, increased transaminases, increased blood alkaline phosphatase, increased gamma-glutamyltransferase<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Nephrolithiasis, renal failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (34%), weight loss (11%)</p>
<p><b>Frequency not reported</b>: Hyponatremia, metabolic acidosis, hypokalemia, hypovolemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Increased lacrimation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (60%), pyrexia (10%)</p>
<p><b>Common</b> (1% to 10%): Edema, pain, chest pain</p>
<p><b>Frequency not reported</b>: Chills<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Sepsis, infection, neutropenic infection, bacterial infection<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Ixempra (ixabepilone)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: mitotic inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ixempra &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer, Metastatic</li>
<li>Breast Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ixabepilone: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (Grade 4) (36%), leukopenia (41%)</p><p><b>Common</b> (1% to 10%): Febrile neutropenia, infection with neutropenia, anemia, thrombocytopenia</p><p><b>Frequency not reported</b>: Coagulopathy, lymphopenia, hemorrhage<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Flushing, rash, dyspnea, bronchospasm, anaphylaxis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (all Grades) (67%), sensory neuropathy (65%), peripheral neuropathy (Grade 3 or 4) (23%), motor neuropathy (16%), taste disorder (12%)</p><p><b>Common</b> (1% to 10%): Headache, dizziness</p><p><b>Frequency not reported</b>: Cognitive disorder, syncope, cerebral hemorrhage, abnormal coordination, lethargy<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Myocardial ischemia, ventricular dysfunction, hot flush </p><p><b>Uncommon</b> (0.1% to 1%): Supraventricular arrhythmia</p><p><b>Frequency not reported</b>: Myocardial infarction, supraventricular arrhythmia, left ventricular dysfunction, angina pectoris, atrial flutter, cardiomyopathy, myocardial ischemia, hypotension, thrombosis, embolism, hypovolemic shock, vasculitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia/arthralgia (39%), musculoskeletal pain (23%)</p><p><b>Frequency not reported</b>: Muscular weakness, muscle spasms, trismus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (53%), abdominal pain (24%), constipation (22%), stomatitis/mucositis, diarrhea</p><p><b>Common</b> (1% to 10%): Dehydration, gastroesophageal reflux disease</p><p><b>Frequency not reported</b>: Enterocolitis, ileus, colitis, impaired gastric emptying, esophagitis, dysphagia, gastritis, GI hemorrhage<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia syndrome (64%), alopecia (31%), nail disorder (24%), skin rash (17%), skin hyperpigmentation (14%)</p><p><b>Common</b> (1% to 10%): Pruritus, skin exfoliation</p><p><b>Frequency not reported</b>: Erythema multiforme</p><p><b>Postmarketing reports</b>: Radiation recall<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, dyspnea, cough</p><p><b>Frequency not reported</b>: Pneumonia, laryngitis, lower respiratory tract infection, pneumonitis, hypoxia, respiratory failure, acute pulmonary edema, dysphonia, pharyngolaryngeal pain<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Acute hepatic failure, jaundice, increased transaminases, increased blood alkaline phosphatase, increased gamma-glutamyltransferase<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Nephrolithiasis, renal failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (34%), weight loss (11%)</p><p><b>Frequency not reported</b>: Hyponatremia, metabolic acidosis, hypokalemia, hypovolemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Increased lacrimation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (60%), pyrexia (10%)</p><p><b>Common</b> (1% to 10%): Edema, pain, chest pain</p><p><b>Frequency not reported</b>: Chills<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Sepsis, infection, neutropenic infection, bacterial infection<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ. </p><h2>More about Ixempra (ixabepilone)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: mitotic inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ixempra &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer, Metastatic</li>
<li>Breast Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>